Roche Pharmaceutical Development and Sales Overview

gRED oncology development programs -2 Molecule Indication Phase # of patients Status Oncology FPI Q2 2021 belvarafenib (RG6185)4 nRASmt CPI-experienced melanoma lb 83 Data presented at ESMO 2021 NME (RG6392) Oncology 60 60 FPI Q4 2021 Partner: 1Xencor, 2BioNTech, ³Relay, "Hanmi Roche CT Identifier NCT04835805 ISRCTN92655 801 138

View entire presentation